The estimated Net Worth of Lawrence Baldini is at least $3.05 million dollars as of 12 November 2018. Lawrence Baldini owns over 35,101 units of Meridian Bioscience stock worth over $2,250,614 and over the last 21 years Lawrence sold VIVO stock worth over $800,815.
Lawrence has made over 7 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently Lawrence sold 35,101 units of VIVO stock worth $681,310 on 12 November 2018.
The largest trade Lawrence's ever made was selling 35,101 units of Meridian Bioscience stock on 12 November 2018 worth over $681,310. On average, Lawrence trades about 2,832 units every 57 days since 2003. As of 12 November 2018 Lawrence still owns at least 66,253 units of Meridian Bioscience stock.
You can see the complete history of Lawrence Baldini stock trades at the bottom of the page.
Lawrence's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny et John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: